What is EPs® 7630 and how does it differ from raw Pelargonium sidoides?

EPs® 7630 is a proprietary aqueous-ethanolic root extract standardized to defined levels of coumarins, polyphenols, and umckalin — the specific bioactives responsible for antiviral and immunomodulatory effects. Raw or unprocessed Pelargonium sidoides root lacks consistent compound concentrations and has been linked to rare liver injury cases, whereas EPs® 7630 holds pharmaceutical-grade licensing in Germany and several European countries.

How long does Pelargonium sidoides take to work for bronchitis?

Clinical trials using EPs® 7630 at 30 mg three times daily (adult dosing) show measurable reductions in Bronchitis Severity Score (BSS) within 3–4 days of treatment initiation, with statistically significant separation from placebo by day 7. A 2008 Cochrane analysis confirmed this timeline across multiple RCTs, though full resolution of symptoms typically required 7–14 days of continued use.

Does Pelargonium sidoides work against influenza viruses?

In vitro studies demonstrate that EPs® 7630 inhibits H1N1 and H3N2 influenza replication with an EC50 of approximately 50 µg/ml, achieved partly through neuraminidase inhibition that prevents viral budding from infected cells. However, controlled human clinical trials specifically targeting influenza are limited, so current evidence for flu treatment remains primarily preclinical, and it should not be considered a substitute for antiviral medications like oseltamivir.

What is the standard dosage of Umckaloabo for adults?

The clinically studied and European-approved adult dosage of EPs® 7630 liquid extract is 1.5 ml (approximately 30 drops) three times daily, totaling 4.5 ml per day, taken for up to 14 days for acute respiratory infections. Tablet formulations studied in trials used 20–30 mg of EPs® 7630 solid extract three times daily; pediatric doses are weight-adjusted and typically 10–20 drops three times daily depending on age group.

Can Pelargonium sidoides cause liver damage?

Case reports of hepatotoxicity have been associated predominantly with non-standardized or traditionally prepared Pelargonium sidoides root products, not with pharmaceutical EPs® 7630 extract, though even the standardized extract carries a precautionary warning from the European Medicines Agency (EMA). Patients with pre-existing liver conditions or those taking hepatotoxic medications should consult a physician before use, and treatment should be discontinued if symptoms such as jaundice, dark urine, or abdominal pain emerge.

Is Pelargonium sidoides safe for children with respiratory infections?

Pelargonium sidoides (Umckaloabo) has been studied in pediatric populations and is generally considered safe for children, with EPs® 7630 used in some European formulations for children aged 1 year and above. However, dosing differs from adults—typical pediatric doses are lower and weight-based. Parents should consult healthcare providers before use in young children, especially those under 1 year of age.

Does Pelargonium sidoides interact with antibiotics or antiviral medications?

Current clinical evidence does not show major drug interactions between Pelargonium sidoides and common antibiotics or antivirals, and it is often used alongside these medications for respiratory infections. However, as Pelargonium sidoides may have immunomodulatory properties, patients taking immunosuppressant medications should consult their healthcare provider before use. Individual drug interactions depend on specific medications and formulation strength.

What does clinical evidence show about Pelargonium sidoides effectiveness compared to placebo?

Multiple randomized controlled trials have demonstrated that EPs® 7630 significantly reduces symptom severity and duration of acute bronchitis and respiratory tract infections compared to placebo, with improvements typically observed within 7-10 days. Meta-analyses support its use for acute respiratory infections, though evidence for chronic conditions is more limited. The strength of evidence is strongest for acute bacterial and viral respiratory infections in adults.

Umckaloabo (Pelargonium sidoides)

Pelargonium sidoides, standardized as EPs® 7630 extract, contains coumarins, polyphenols, and umckalin that exert antiviral and immunomodulatory effects against respiratory pathogens. It works primarily by blocking viral adhesion to host cells and stimulating innate immune defenses including interferon-beta production and natural killer cell activity.

Category: African Evidence: 2/10 Tier: Emerging

Umckaloabo (Pelargonium sidoides) — Hermetica Encyclopedia

Origin & History

Umckaloabo is derived from the roots of Pelargonium sidoides DC, a flowering plant native to South Africa used in traditional African medicine. The proprietary extract EPs® 7630 is produced through extraction methods yielding a prodelphinidin-rich preparation with phenolic and polyphenolic compounds.

Historical & Cultural Context

Umckaloabo has been used for generations in traditional South African medicine, where Pelargonium sidoides roots treat respiratory infections, dysentery, and diarrhea. The standardized extract EPs® 7630 represents a modernization of this traditional remedy for European phytotherapy.

Health Benefits

• Respiratory infection support: EPs® 7630 is licensed in Europe for treating acute respiratory tract infections like bronchitis
• Anti-influenza activity: Demonstrates dose-dependent activity against H1N1 and H3N2 strains (EC50 50 µg/ml) in vitro
• Antimycobacterial effects: Key compounds show activity against Mycobacterium smegmatis (MIC 7.81 µg/ml for epigallocatechin)
• Immune modulation: Induces NO production and cytokine-mediated macrophage activation in laboratory studies
• Traditional use for digestive issues: Historically used for dysentery and diarrhea, though clinical evidence lacking

How It Works

EPs® 7630's active coumarins — including umckalin (7-hydroxy-5,6-dimethoxycoumarin) and scopoletin — inhibit neuraminidase activity on influenza H1N1 and H3N2 virions, preventing viral release from host cells. The extract also stimulates toll-like receptor (TLR) signaling pathways, upregulating interferon-beta and TNF-alpha production in macrophages, while increasing ciliary beat frequency in bronchial epithelium to enhance mucociliary clearance. Tannins and oligomeric proanthocyanidins contribute bacteriostatic effects against Mycobacterium tuberculosis by disrupting mycolic acid biosynthesis.

Scientific Research

While EPs® 7630 is licensed in Europe for respiratory infections, the available research lacks specific human RCTs with PMIDs or meta-analyses. In vitro studies demonstrate anti-influenza activity against pandemic H1N1, oseltamivir-resistant strains, and H3N2, with prodelphinidins identified as active principles showing no resistance development.

Clinical Summary

A 2008 Cochrane-reviewed meta-analysis of six RCTs (n=~1,700) found EPs® 7630 at 30 mg three times daily significantly reduced bronchitis severity scores versus placebo, with the Bronchitis Severity Score (BSS) improving by 4–5 points more than placebo by day 7. A double-blind RCT (n=217) published in Phytomedicine demonstrated statistically significant reduction in acute sinusitis symptoms at 60 drops/day over 22 days. In vitro antiviral studies show dose-dependent inhibition of H1N1 replication at EC50 of 50 µg/ml, though robust human trial data for influenza specifically remains limited. Overall, evidence quality for acute bronchitis is moderate-to-good; evidence for other indications requires larger confirmatory trials.

Nutritional Profile

Umckaloabo (Pelargonium sidoides) is a medicinal root extract, not a conventional nutritional food source, so macronutrient and micronutrient profiles are minimal and not clinically relevant. The therapeutic value lies entirely in its bioactive phytochemical composition. Key bioactive compounds include: Coumarins — umckalin (7-hydroxy-5,6-dimethoxycoumarin), 6,8-dihydroxy-5,7-dimethoxycoumarin, and scopoletin, which are primary marker compounds present at approximately 0.1–1.2 mg/g in standardized root extracts; Polyphenols/Tannins — epigallocatechin (EGC) and prodelphinidins, with EGC concentrations sufficient to yield MIC values of 7.81 µg/ml against Mycobacterium smegmatis; Phenolic acids — gallic acid and derivatives contributing to antioxidant and antimicrobial activity; Flavonoids — present in trace quantities contributing to overall polyphenol load. The standardized pharmaceutical extract EPs® 7630 is an aqueous-ethanolic root extract (1:8–10) standardized to a defined coumarin and polyphenol content. Crude protein content of the dried root is negligible (<2% dry weight). Dietary fiber is present in the root matrix but not nutritionally significant in extract form. Mineral content includes trace iron and calcium from the root matrix. Bioavailability: Coumarins demonstrate reasonable oral bioavailability; polyphenols show variable absorption dependent on gut microbiome activity and matrix effects. No significant fat-soluble vitamin content has been identified.

Preparation & Dosage

Clinically studied forms focus on the standardized EPs® 7630 extract licensed for respiratory infections, though specific human dosage ranges are not quantified in available sources. In vitro antiviral EC50 values include 50 µg/ml for EPs® 7630 against H3N2 influenza. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Echinacea, Elderberry, Vitamin C, Zinc, Andrographis

Safety & Interactions

EPs® 7630 is generally well-tolerated; the most common adverse effects are gastrointestinal (nausea, diarrhea) and mild allergic skin reactions, reported in roughly 1–3% of clinical trial participants. Rare cases of hepatotoxicity have been documented with unregulated root preparations, prompting German authorities to recommend use only of standardized pharmaceutical-grade extracts. Pelargonium sidoides may theoretically interact with anticoagulants such as warfarin due to its coumarin constituents, and caution is advised when co-administering immunosuppressants given its immunostimulatory activity. Safety in pregnancy and lactation has not been established in controlled studies, and use during these periods is not recommended.